期刊
DIGESTIVE DISEASES AND SCIENCES
卷 53, 期 12, 页码 3055-3064出版社
SPRINGER
DOI: 10.1007/s10620-008-0294-y
关键词
Sorafenib; Cyclin D1; Cyclin E; Barrett's esophagus; Esophageal adenocarcinoma
资金
- Digestive Diseases and Related Disorders, Israel
- Digestive Diseases Research Core Center [P30DK42086, CA036745]
- Samuel Freedman Research Laboratories for Gastrointestinal Cancer Research, USA
Background and purpose Current therapies offer scant benefit to patients with advanced esophageal adenocarcinoma. We investigated the effects of Sorafenib, a multifunctional kinase inhibitor, on several growth regulatory pathways that control cell growth and survival in SEG-1 cells derived from Barrett's adenocarcinoma. Methods SEG-1 cells were exposed to acidified medium or taurocholic acid, with and without pre-incubation with Sorafenib. Cyclin D1 and E, c-Myc, and Bcl-2 expression levels as well as STAT3 activations were determined by Western blotting. Cyclin D1 mRNA was measured by real-time PCR. Apoptosis was assessed by TUNEL assay. Results Sorafenib significantly inhibited SEG-1 cell proliferation stimulated by acid or bile acid treatments and reduced cell survival. This drug significantly reduced the up-regulations of cyclin D1, cyclin E, c-Myc, and Bcl-2 as well as the activation of STAT3 in SEG-1 cells. Conclusions These results support a rational basis for future clinical studies to assess the therapeutic benefit of Sorafenib in esophageal adenocarcinoma.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据